Needham Maintains Buy on Evommune, Lowers Price Target to $25
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate
Evommune to Present at Upcoming Investor Conferences
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks Transcript
Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Evommune Announces $30 Million Private Placement
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Evommune Receives Exclusive License From Hinova Pharmaceuticals To Develop, Manufacture, Commercialize EVO570 Outside China; Hinova To Get $30M Upfront Payment
UBS Initiates Coverage On Evommune with Neutral Rating, Announces Price Target of $8
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
Evommune Consensus Price Target Decreased by 13.25% to $24.48
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.